# Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder

> **NCT04708834** · PHASE3 · TERMINATED · sponsor: **Biohaven Pharmaceuticals, Inc.** · enrollment: 772 (actual)

## Conditions studied

- Obsessive Compulsive Disorder

## Interventions

- **DRUG:** Troriluzole (BHV-4157)

## Key facts

- **NCT ID:** NCT04708834
- **Lead sponsor:** Biohaven Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-30
- **Primary completion:** 2026-02-13
- **Final completion:** 2026-02-13
- **Target enrollment:** 772 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04708834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04708834, "Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04708834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*